TrialInternational journal of cancer2022

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.

Elodie Maille et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.